Terms: = Liver cancer AND PSA AND Staging
15 results:
1. Identification and Validation of the Prognostic Impact of Metastatic Prostate cancer Phenotypes.
Labe SA; Wang X; Lehrer EJ; Kishan AU; Spratt DE; Lin C; Morgans AK; Ponsky L; Garcia JA; Garrett S; Wang M; Zaorsky NG
Clin Genitourin Cancer; 2022 Aug; 20(4):371-380. PubMed ID: 35383004
[TBL] [Abstract] [Full Text] [Related]
2. Single-Center Comparison of [
Mirzaei S; Lipp R; Zandieh S; Leisser A
Curr Oncol; 2021 Oct; 28(5):4167-4173. PubMed ID: 34677271
[TBL] [Abstract] [Full Text] [Related]
3. Prospective intra-individual blinded comparison of [
Pattison DA; Debowski M; Gulhane B; Arnfield EG; Pelecanos AM; Garcia PL; Latter MJ; Lin CY; Roberts MJ; Ramsay SC; Thomas PA
Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):763-776. PubMed ID: 34383089
[TBL] [Abstract] [Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract] [Full Text] [Related]
5. Application of Cu-64 NODAGA-PSMA PET in Prostate cancer.
Sevcenco S; Klingler HC; Eredics K; Friedl A; Schneeweiss J; Knoll P; Kunit T; Lusuardi L; Mirzaei S
Adv Ther; 2018 Jun; 35(6):779-784. PubMed ID: 29777523
[TBL] [Abstract] [Full Text] [Related]
6. Multiparametric [11C]Acetate positron emission tomography-magnetic resonance imaging in the assessment and staging of prostate cancer.
Polanec SH; Andrzejewski P; Baltzer PAT; Helbich TH; Stiglbauer A; Georg D; Karanikas G; Susani M; Wadsak W; Margreiter M; Mitterhauser M; Brader P; Pinker K
PLoS One; 2017; 12(7):e0180790. PubMed ID: 28719629
[TBL] [Abstract] [Full Text] [Related]
7. Pattern and Distribution of Distant Metastases in Anaplastic Prostate Carcinoma: A Single-Institute Experience With 101 Patients.
Ganeshan D; Aparicio AM; Morani A; Kundra V
AJR Am J Roentgenol; 2017 Aug; 209(2):327-332. PubMed ID: 28590819
[TBL] [Abstract] [Full Text] [Related]
8. Non-invasive assessment of inter-and intrapatient variability of integrin expression in metastasized prostate cancer by PET.
Beer AJ; Schwarzenböck SM; Zantl N; Souvatzoglou M; Maurer T; Watzlowik P; Kessler H; Wester HJ; Schwaiger M; Krause BJ
Oncotarget; 2016 May; 7(19):28151-9. PubMed ID: 27058620
[TBL] [Abstract] [Full Text] [Related]
9. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
[TBL] [Abstract] [Full Text] [Related]
10. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer.
Vuky J; Porter C; Isacson C; Vaughan M; Kozlowski P; Picozzi V; Corman J
Cancer; 2009 Feb; 115(4):784-91. PubMed ID: 19130458
[TBL] [Abstract] [Full Text] [Related]
11. Serum levels of free and total prostate-specific antigen in males with liver cirrhosis.
Kubota Y; Sasagawa I; Sinzawa H; Kunii T; Itoh K; Miura H; Imai K; Nakada T
Eur Urol; 1999 Nov; 36(5):409-12. PubMed ID: 10516451
[TBL] [Abstract] [Full Text] [Related]
12. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma.
Díaz-Martín MA; Traba ML; De La Piedra C; Guerrero R; Méndez-Dávila C; De La Peña EG
Scand J Clin Lab Invest; 1999 Apr; 59(2):125-32. PubMed ID: 10353326
[TBL] [Abstract] [Full Text] [Related]
13. Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer.
Figg WD; Ammerman K; Patronas N; Steinberg SM; Walls RG; Dawson N; Reed E; Sartor O
Cancer Invest; 1996; 14(6):513-7. PubMed ID: 8951355
[TBL] [Abstract] [Full Text] [Related]
14. A more objective staging of advanced prostate cancer--routine recognition of malignant endocrine structures: the assessment of serum TPS, psa, and NSE values.
Tarle M; Frković-Grazio S; Kraljić I; Kovacić K
Prostate; 1994; 24(3):143-8. PubMed ID: 7509485
[TBL] [Abstract] [Full Text] [Related]
15. The staging of M+ disease.
Bouffioux C; Bollack C; Scher H
Prog Clin Biol Res; 1990; 357():185-91. PubMed ID: 2217462
[TBL] [Abstract] [Full Text] [Related]
